CTLA4 and lung cancer: Experimental validation revealed that MAP reduced PD‐L1 expression by targeting E3 ubiquitin ligase speckle‐type zinc finger structural protein (SPOP), and the combination of MAP and anti‐CTLA4 in vivo significantly enhanced the antitumor effect, providing a new alternative for the clinical treatment of colorectal and lung cancer.